Nevro Corp. logo
Nevro Corp. NVRO
report update icon

Quarterly report 2024-Q3
added 06-13-2026

Nevro Corp. Balance Sheet 2024-2011 | NVRO

Brief overview of Nevro Corp.'s balance sheet strength

The balance sheet is assessed across five available annual reports spanning 2020 to 2024.

Assets finished at $553.8 million versus $789.4 million initially, losing -29.8%. The balance sheet contracted.

Liabilities grew faster than assets: -19.5% versus -29.8%. A substantial part of expansion was externally funded.

Equity finances 41.7% of the balance sheet, compared with 49.2% at the start. The cushion remains adequate.

Net debt equals roughly 0.4x of equity. This is a moderate load and leaves room for maneuver.

Cash accounts for 17.1% of assets versus 5.6% initially. The change indicates the degree of financial flexibility.

The accumulated result is -$812.8 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Balance sheet takeaway

Taken together, Nevro Corp.'s balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.

Annual Balance Sheet Nevro Corp.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

93.4 M 113 M 71.7 M 121 M 101 M 267 M 314 M 329 M 332 M 39.3 M 146 M -12.4 M -5.62 M -

Long Term Debt

188 M 211 M 187 M 151 M 142 M 160 M 152 M 145 M 138 M 19.7 M 19.5 M - - -

Long Term Debt Current

318 K 5.72 M 5.2 M 4.59 M 3.88 M 3.5 M - - - - - - - -

Total Non Current Liabilities

- - - - - 183 M 155 M 147 M 139 M 20.2 M 19.6 M 62 K 248 K -

Total Current Liabilities

103 M 83.4 M 79.2 M 82.2 M 239 M 70.6 M 62.4 M 58 M 42.2 M 36.4 M 10.8 M - - -

Total Liabilities

323 M 343 M 279 M 271 M 401 M 253 M 218 M 205 M 182 M 56.6 M 30.4 M 7.97 M 5.5 M -

Retained Earnings

-813 M -699 M -607 M -624 M -493 M -410 M -306 M -258 M -221 M -189 M -122 M -91.2 M -65 M -

Total Assets

554 M 636 M 602 M 575 M 789 M 470 M 463 M 454 M 431 M 291 M 202 M 75.4 M 49.1 M -

Cash and Cash Equivalents

94.5 M 104 M 120 M 34.7 M 44.6 M 65.4 M 51.3 M 42.8 M 41.4 M 87 M 25.3 M 12.4 M 5.62 M -

Book Value

231 M 293 M 324 M 304 M 388 M 216 M 245 M 249 M 249 M 235 M 172 M 67.4 M 43.6 M -

Total Shareholders Equity

231 M 293 M 324 M 304 M 388 M 216 M 245 M 249 M 249 M 235 M 172 M -85.8 M -61.8 M -

All numbers in USD currency

Quarterly Balance Sheet Nevro Corp.

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

184 M 181 M 215 M 211 M 188 M 187 M 187 M 187 M 187 M 186 M 186 M 151 M 149 M 146 M 144 M 142 M 140 M 137 M 162 M 160 M 158 M 156 M 154 M 152 M 151 M 149 M 147 M 145 M 143 M 142 M 140 M 138 M 136 M 135 M 138 M 19.7 M 19.7 M 30.2 M 30.8 M 31.3 M - - - - - - - - - - - - - - -

Total Liabilities

322 M 329 M 318 M 343 M 276 M 275 M 273 M 279 M 281 M 294 M 292 M 271 M 263 M 241 M 409 M 401 M 399 M 379 M 245 M 253 M 250 M 246 M 244 M 218 M 207 M 204 M 202 M 205 M 194 M 180 M 175 M 182 M 172 M 166 M 45.7 M 56.6 M 43.3 M 35.8 M 33.1 M 30.4 M 8.76 M 30.4 M 30.4 M 7.97 M 7.97 M - - - - - - - - - -

Retained Earnings

-760 M -744 M -725 M -699 M -690 M -667 M -642 M -607 M -588 M -670 M -645 M -624 M -594 M -544 M -522 M -493 M -486 M -476 M -435 M -410 M -396 M -378 M -350 M -306 M -296 M -285 M -275 M -258 M -254 M -247 M -236 M -221 M -211 M -207 M -199 M -189 M -175 M -156 M -136 M -122 M -114 M -122 M -122 M -91.2 M -91.2 M - - - - - - - - - -

Total Assets

596 M 603 M 596 M 636 M 562 M 570 M 574 M 602 M 606 M 524 M 533 M 575 M 582 M 600 M 776 M 789 M 778 M 753 M 460 M 470 M 448 M 448 M 458 M 463 M 451 M 450 M 445 M 454 M 438 M 421 M 418 M 431 M 420 M 412 M 274 M 291 M 288 M 297 M 192 M 202 M 56.1 M 202 M 202 M 75.4 M 75.4 M - - - - - - - - - -

Cash and Cash Equivalents

72 M 74.7 M 90.3 M 104 M 65.2 M 65.2 M 64.2 M 120 M 131 M 109 M 49.5 M 34.7 M 80.9 M 146 M 86.5 M 44.6 M 119 M 277 M 136 M 65.4 M 49.3 M 62.8 M 40.7 M 51.3 M 21.4 M 40.8 M 27.6 M 42.8 M 44 M 24.9 M 19.2 M 41.4 M 42.7 M 50.7 M 48.8 M 87 M 87.6 M 58.7 M 22 M 25.3 M 14.5 M 25.3 M 25.3 M 12.4 M 12.4 M - - 5.62 M - - - 11.3 M - - -

Book Value

274 M 274 M 279 M 293 M 286 M 295 M 301 M 324 M 325 M 230 M 240 M 304 M 319 M 358 M 366 M 388 M 380 M 374 M 215 M 216 M 198 M 202 M 214 M 245 M 244 M 246 M 243 M 249 M 244 M 241 M 243 M 249 M 248 M 246 M 229 M 235 M 244 M 262 M 159 M 172 M 47.4 M 172 M 172 M 67.4 M 67.4 M - - - - - - - - - -

Total Shareholders Equity

274 M 274 M 279 M 293 M 286 M 295 M 301 M 324 M 325 M 230 M 240 M 304 M 319 M 358 M 366 M 388 M 380 M 374 M 215 M 216 M 198 M 202 M 214 M 245 M 244 M 246 M 243 M 249 M 244 M 241 M 243 M 249 M 248 M 246 M 229 M 235 M 244 M 262 M 159 M 172 M -106 M 172 M 172 M -85.8 M -85.8 M - - -61.8 M - - - -44.7 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Nevro Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
AxoGen AxoGen
AXGN
$ 48.73 1.42 % $ 2.24 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 18.34 0.55 % $ 1.41 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 3.87 % $ 14.6 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 82.22 0.02 % $ 4.48 B britainBritain
LENSAR LENSAR
LNSR
$ 8.2 0.24 % $ 98.1 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.27 1.67 % $ 631 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.34 0.1 % $ 434 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.4 10.38 % $ 24.9 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inogen Inogen
INGN
$ 5.75 0.17 % $ 153 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.84 0.79 % $ 2.18 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA